The knowledge base
What the evidence actually shows
Every page answers one real GLP-1 question, grades the answer on the 8-rung Evidence Ladder, and links the primary sources. Browse by topic, filter by strength, or search.
52 graded answers · 8 topics · 353+ primary sources · no doses, no sourcing
How we grade
The tool every page here runs on
Rank any claim by how much weight the evidence can bear — strongest at the top, theory and danger at the bottom. Every answer below carries its rung, in plain sight.
How the ladder works →↑ Stronger — proven in people
Strong evidenceProven in people
- 1Established
- 2Supported but limited
Limited evidenceSome human data — not settled yet
- 3Emerging
- 4Observational only
Early signalAnimal or anecdote only — not shown in people
- 5Preclinical
- 6Anecdotal
Theory onlyNo human efficacy data
- 7Speculative
- 8Unsafe to state
↓ Weaker — theory only
Start here
The plain-English foundations: what these medicines are, how the brands map, and the honest numbers.
What is a GLP-1? A plain-English guide to how these medicines work
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat; it nudges insulin up, glucagon down, stomach-emptying slower, and appetite lower. The medicines people call 'GLP-1s' — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and others — are engineered drugs that switch on the same receptor as that natural hormone, but are built to last days instead of minutes. They're approved to treat type 2 diabetes and, for several products, obesity; the most common side effects are gastrointestinal.
Read the evidence →Strong evidenceRung 1 of 8 · Established- 1The Evidence Ladder: how to judge any GLP-1 claimYou can judge almost any health claim by asking one question: how strong is the evidence behind it? The Evidence Ladder sorts claims into eight rungs, from established human evidence at the top to claims that outrun their evidence so badly they are unsafe to state at the bottom. It does not tell you what is true — it tells you how much confidence a claim has earned.
- 1GLP-1 medicines compared: every brand, side by sideThe GLP-1 brands map onto just a few molecules: Ozempic, Wegovy and Rybelsus are all semaglutide (Novo Nordisk); Mounjaro and Zepbound are both tirzepatide (Eli Lilly); and Foundayo is orforglipron, a newer pill. Within each molecule, the different brand names mostly reflect the approved use (diabetes vs weight management) and how you take it (weekly injection vs daily pill) — not a different drug. Average weight loss runs about 15% for semaglutide, ~20% for tirzepatide, and ~11% for the orforglipron pill in their main trials.
- 1GLP-1 medicines by the numbers: the key statistics, honestly sourcedThese are trial averages from separate studies — not head-to-head, and not a prediction for any one person. Average weight loss ran about 21% for tirzepatide (Zepbound, SURMOUNT-1), about 16–17% for the oral-semaglutide pill (OASIS), about 15% for semaglutide (Wegovy, STEP 1), and about 11% for the orforglipron pill (Foundayo, ATTAIN-1); the investigational triple-agonist retatrutide reported about 28% at its top dose in a phase-3 readout that isn't yet published. The most common side effects are gastrointestinal (on the Wegovy label, nausea 44% vs 16% on placebo). Serious problems (gallbladder disease, pancreatitis) are uncommon; a rare eye condition (NAION) is an emerging, unproven signal. After stopping, trials show most of the lost weight returns over about a year. This page collects the key numbers, each tied to its source and labeled by how strong that evidence is.
Choosing & comparing
Which one, brand vs. molecule, switching, cost — and how to judge any claim.
Semaglutide vs tirzepatide: how they really compare
Both are highly effective GLP-1-based medicines with broadly similar gastrointestinal side-effect profiles and the same class warnings (boxed rodent-thyroid, pancreatitis, gallbladder, hypoglycemia in combination). The clearest difference is average weight loss: in the head-to-head SURMOUNT-5 obesity trial, tirzepatide produced more weight loss than semaglutide (−20.2% vs −13.7% at 72 weeks), and tirzepatide is a dual GIP/GLP-1 agonist while semaglutide acts on GLP-1 alone. But 'more on average' is not 'right for you.' A few genuinely drug-specific points matter: tirzepatide's label carries an oral-contraception warning that semaglutide's does not; semaglutide's diabetes label carries a diabetic-retinopathy warning; the NAION eye signal is better characterized for semaglutide; and the cardiovascular evidence differs in kind (semaglutide has placebo-controlled obesity outcomes from SELECT; tirzepatide has an active-comparator non-inferiority diabetes trial, SURPASS-CVOT). Which drug, and whether to switch, is a clinician decision.
Read the evidence →Strong evidenceRung 1 of 8 · Established- 1Ozempic vs Wegovy vs Mounjaro vs Zepbound: the brand decoderFour brands, two molecules. Ozempic and Wegovy are both semaglutide, a GLP-1 receptor agonist. Mounjaro and Zepbound are both tirzepatide, which adds a second incretin target, GIP. Within each pair, the diabetes brand and the weight-management brand share the molecule but differ in approved use.
- 1Are Ozempic and Wegovy the same drug?Yes — Ozempic and Wegovy are the same molecule, semaglutide, from the same manufacturer. They differ by brand name, FDA-approved use, and approved dose range: Ozempic is approved for type 2 diabetes, Wegovy for chronic weight management. Those different labels are why insurers cover them differently.
- 2Zepbound vs Wegovy: what the head-to-head evidence showsZepbound (tirzepatide) and Wegovy (semaglutide) are different molecules. In SURMOUNT-5, the one head-to-head obesity trial, Zepbound produced greater average weight loss than Wegovy. Their side-effect profiles are broadly similar, but their approved uses differ — and group averages don't predict your individual result. Which fits you is a clinical question.
- 2Switching between GLP-1 medicines: what to knowPeople switch GLP-1 medicines for three main reasons: not enough results, side effects they cannot tolerate, or problems with cost and supply. The molecules differ in how they work, how much weight they tend to produce on average, and their approved uses. Whether to switch, and to what, is a prescriber's decision — not a self-directed change.
- 1GLP-1 cost and access in 2026: how pricing and coverage workIn 2026, what you pay for a GLP-1 depends less on the sticker price than on the path: list price, insurer or PBM coverage with prior authorization, manufacturer cash-pay and savings programs, or Medicare. Government rules differ sharply from commercial plans, and a temporary Medicare program now covers some obesity use.
Side effects & managing them
What’s common, what’s concerning, and how to handle each one.
GLP-1 side effects: common, uncommon, and when to ask for help
Across large trials, the most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually mild-to-moderate, dose-related, and easing with time. Serious problems such as pancreatitis, gallbladder disease, and bowel obstruction are uncommon but real and well-documented on the labels. Most early discomfort is expected; specific red-flag symptoms are not, and warrant prompt clinical contact.
Read the evidence →Strong evidenceRung 1 of 8 · Established- 1GLP-1 nausea: why it happens, how long it lasts, and what actually helpsNausea is the most common side effect of GLP-1 medicines. It happens because they slow how fast your stomach empties and act on the brain's appetite and nausea centres, so it's usually worst in the first weeks and just after a dose increase — and for most people it eases as the body adjusts. Smaller, blander, low-fat meals, eating slowly, staying hydrated, and a slow dose increase are what actually help. A few symptoms — relentless vomiting or being unable to keep fluids down, signs of dehydration, or severe belly pain (which may spread to the back) — are reasons to call your clinician rather than wait it out.
- 1GLP-1 fatigue: why you feel drained, and what actually helpsFeeling drained is a common side effect of GLP-1 medicines, and it's listed on the label. It mostly comes from the medicine working: blunted appetite means many people eat and drink less and lose weight quickly, and lower calorie and fluid intake, GI side effects, and shifting blood sugar can all leave you tired — especially while the dose is being increased. For most people it eases as the body adjusts. Eating regular balanced meals with protein (even when appetite is low), steady fluids, gentle movement, and pacing yourself during dose increases are what help most. A few signs — fatigue with chest pain or breathlessness, severe dehydration, or symptoms of very low blood sugar — mean call your clinician rather than wait.
- 2GLP-1 heartburn and acid reflux: why it happens, and what helpsHeartburn and acid reflux are common on GLP-1 medicines, and GERD and indigestion are listed on the labels. They likely happen because these drugs slow stomach emptying, so food and acid sit longer and can rise back up; existing reflux can feel worse. Smaller lower-fat meals, avoiding triggers, staying upright after eating, and eating slowly help. Trouble swallowing, vomiting blood, or any chest pain mean get medical help.
- 2GLP-1 sulfur burps: why the rotten-egg burps happen, and what helpsSulfur burps — burps that smell like rotten eggs — are a commonly reported and usually harmless GLP-1 side effect, not a sign something is seriously wrong. The leading explanation is that these medicines slow how fast the stomach empties, so food sits longer and gut bacteria ferment it, releasing hydrogen sulfide (the rotten-egg gas); sulfur burps specifically are lightly studied, so this is well-reasoned mechanism rather than settled trial data. They often come with bloating and a full feeling. Smaller, lower-fat meals eaten slowly, avoiding fizzy drinks, temporarily cutting back on very high-sulfur foods, staying hydrated, and a gentle walk after meals are what help. They're unpleasant but not dangerous on their own — though sulfur burps together with persistent vomiting, severe belly pain, or signs of a blockage are reasons to call your clinician.
- 1GLP-1 dizziness and lightheadedness: why it happens, and what helpsDizziness and lightheadedness are commonly reported on GLP-1 medicines and listed on the labels. They're usually thought to come not from the drug acting on your head directly but from its knock-on effects: eating and drinking less can lead to dehydration and low blood sugar, and blood pressure can dip, especially when you stand up quickly. It's more likely during dose increases and when your intake is lower than usual. For most people it's manageable: standing up slowly, staying hydrated, not going too long without food, and cooling off in hot environments are what help most. A few patterns — fainting, dizziness with chest pain or palpitations, slurred speech or one-sided weakness, or severe spinning that stops you functioning — are not ordinary lightheadedness and mean get medical help.
- 1GLP-1 constipation: why it happens and what to discuss with a clinicianConstipation is a common, recognized side effect of GLP-1 (and dual GIP/GLP-1) receptor agonists, listed on approved drug labels and reported across the large weight and diabetes trials. It happens largely because these medicines slow how fast the stomach and gut move food along — the same action that curbs appetite — and because eating and drinking less leaves stool drier and slower. It is usually mild and tends to ease, but sudden severe constipation with belly pain or vomiting is a reason to seek care.
- 4GLP-1 hair loss: why it happens and whether it's permanentMost GLP-1–associated hair loss is telogen effluvium — temporary, diffuse shedding triggered by rapid weight loss rather than a direct drug toxicity. The follicles are not destroyed, so hair typically regrows within months once weight stabilizes and nutrition recovers. Drug labels report it as uncommon and tied to how much weight is lost.
- 4Loose skin on a GLP-1 ('Ozempic arms' and 'Ozempic face')Loose skin after major weight loss is real and common — and it is not caused by GLP-1 medicines specifically. It's a general consequence of large, relatively rapid weight loss, seen for decades after bariatric surgery. When skin is stretched by excess weight for years, its collagen and elastic fibers are physically damaged, so when the fat underneath leaves, the skin often can't fully recoil. How much loose skin someone gets depends on age, genetics, how much and how fast they lost, how long they were heavy, sun exposure, and smoking — not on which drug produced the loss. 'Ozempic face' is the same story on the face: losing fat that provided volume, plus normal skin aging. The drug is the cause of the weight loss, not a unique cause of the skin change.
- 2GLP-1s and sleep: apnea, and the 'vivid dreams' questionTwo very different sleep claims travel together and deserve opposite grades. The proven one is obstructive sleep apnea: tirzepatide, as Zepbound, is FDA-approved (December 2024) for moderate-to-severe OSA in adults with obesity — the first drug ever approved for sleep apnea — based on trials where it cut the apnea-hypopnea index roughly in half. The unproven one is 'vivid dreams': many people report intense or strange dreams on GLP-1s, but there is no trial evidence that these drugs cause them, and several things (weight loss, changed eating and alcohol, improved apnea) could explain it. Don't let the real apnea approval lend credibility to the dream claim.
- 2Ozempic face: is it real, is it the drug or the weight loss, and is it permanent?"Ozempic face" is real but misnamed. It's the gaunt, hollow-cheeked, or loosened look some people notice after large, fast weight loss on a GLP-1 medicine — and the best evidence, including a 2025 systematic review, says it is facial fat and volume loss driven by the weight loss itself, not the drug chemically ageing your skin. The same change follows comparable weight loss by any route, and it happens with tirzepatide (Mounjaro/Zepbound) too — "Mounjaro face" is the same thing under a different brand. It isn't simple to reverse: some laxity settles as weight stabilises, but rapid loss in older, less elastic skin may not bounce back on its own, and regained weight rarely refills the face the way it left. The pace of loss, and protecting muscle, are the levers people actually have; any cosmetic decision belongs with a clinician.
- 1Semaglutide side effects: what the evidence actually showsMost semaglutide side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually mild-to-moderate, tied to dose increases, and easing over time; this is established from large randomized trials and the FDA label. Serious problems (pancreatitis, gallbladder disease, bowel obstruction, kidney injury from dehydration) are uncommon but real and documented. Newer signals — a rare eye condition (NAION) and gastroparesis-related litigation — are real but largely observational, not proof of a precise risk. A short list of red-flag symptoms warrants prompt clinical contact.
- 1Tirzepatide side effects: what the evidence actually showsMost tirzepatide side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually mild-to-moderate, tied to dose increases, and easing over time; this is established from the large SURMOUNT and SURPASS trials and the FDA label. That 'established' grade applies to those common GI effects; the rarer or more serious signals — NAION, gastroparesis, and muscle-function loss — are graded individually in their own sections, because the evidence behind each differs. Serious problems (pancreatitis, gallbladder disease, kidney injury from dehydration) are uncommon but real and documented, and tirzepatide carries the same boxed thyroid warning as its class. One tirzepatide-specific point matters: its label warns it can make oral birth-control pills less reliable. Newer or rarer signals — an eye condition (NAION) and gastroparesis-related litigation — are real but largely observational, and the eye signal is best characterized for semaglutide, not tirzepatide. A short list of red-flag symptoms warrants prompt clinical contact.
- 3GLP-1's lesser-known side effects: what the emerging signals actually showBeyond the common gastrointestinal effects, GLP-1 medicines carry a second tier of rarer and newer side-effect signals — and their evidence is very uneven, which is the whole point of this page. Some are established: gallbladder problems (cholelithiasis) are a real, if uncommon, effect, partly driven by rapid weight loss. Some are genuinely emerging and unsettled: a possible link to a rare eye condition called NAION is being actively studied, flagged by the WHO and European regulators in 2025, but not proven to be caused by the drug and still very rare in absolute terms. Some point the other way: an early worry about depression and suicidal thoughts has, so far, not held up — regulators reviewed it and found no established causal link. And some are almost purely anecdotal, like feeling cold, reported widely online but with essentially no clinical evidence behind them. This page grades each signal on its own merits so you can tell a documented risk from a viral worry — and know the few that mean seek care now.
Nutrition, muscle & the body
Protecting muscle, protein, eating, and exercise while you lose.
GLP-1 muscle loss: what the evidence really says
Like any substantial weight loss, the weight people lose on GLP-1 medicines is a mix of fat and lean (muscle) mass, and the lean portion is broadly in the range seen with diet-based weight loss. What protects muscle is not the drug but adequate protein and resistance training. Whether the lean-mass loss on these drugs causes lasting harm to strength or function is still being studied.
Read the evidence →Strong evidenceRung 2 of 8 · Supported but limited- 2How much protein do GLP-1 users need? Evidence, not hypeStrong evidence shows that a higher-protein diet plus resistance training preserves more muscle during any weight loss, and that a meaningful share of GLP-1 weight loss is lean mass — so protein matters more, not less, when appetite drops. But the single optimal protein target for GLP-1 users specifically has not been established, so general higher-protein ranges studied during dieting are a starting point to personalize with a clinician, not a fixed prescription.
- 2What to eat on a GLP-1 when you have no appetiteWhen appetite is low on a GLP-1, prioritize protein at every meal, then nutrient-dense whole foods, fluids, and fiber as tolerated. A joint advisory from four major nutrition and obesity societies recommends protein-first eating plus strength training to protect muscle, smaller frequent meals for nausea, and attention to micronutrients as overall intake falls.
- 2GLP-1s and exercise: why weight loss doesn’t automatically increase activityWeight loss on GLP-1 medicines does not automatically translate into more physical activity; eating much less can leave your energy and spontaneous movement flat or lower, not higher. The medicine acts on appetite, not on the drive to exercise, so the activity that protects muscle and function has to be added deliberately. The most direct supporting evidence comes from a trial where exercise was intentionally combined with the drug rather than left to happen on its own.
Results, plateaus & stopping
Plateaus, what happens when you stop, and keeping it off.
Why you stop losing weight on a GLP-1: plateaus explained
A plateau is expected, not failure. In trials, weight loss slows and levels off as the body defends a new set point — resting metabolism falls and hunger hormones adjust. Most people on tirzepatide plateaued near 24 to 36 weeks; on semaglutide, loss continued for over a year and was levelling off near the end of the 68-week trial. A months-in stall means the drug did its work, not that it quit.
Read the evidence →Strong evidenceRung 2 of 8 · Supported but limited- 1What happens when you stop GLP-1 medications?In randomized trials, stopping a GLP-1 medicine (such as semaglutide or tirzepatide) is typically followed by substantial weight regain over the following year, with much of the metabolic improvement — blood pressure, blood sugar, lipids — drifting back toward where it started. This reflects the biology of obesity as a chronic, relapsing condition, not a personal failure; the drug manages the condition while taken rather than curing it. Whether any individual can hold their loss after stopping, and how best to taper or transition, is not settled and should be planned with a clinician.
- 3Keeping weight off after stopping a GLP-1Stopping a GLP-1 is usually followed by substantial weight regain — about two-thirds of the loss within a year in trial extensions. The lifestyle levers with the best evidence for blunting that are adequate protein and resistance training; in one trial, people who built an exercise habit held their loss better after stopping. Plan the transition with a clinician.
The medicines & the market
Newer drugs, the pills, fatty-liver, microdosing, and the compounding ban.
Retatrutide: what we know, and what we don’t
Retatrutide is an investigational GIP/GLP-1/glucagon triple-agonist that produced the largest average weight loss of any drug in its class in early trials. As of mid-2026 it is not approved by the FDA, EMA, or MHRA for any use; its Phase 3 program is still reading out, and the only legitimate way to take it is inside a clinical trial. Any “retatrutide” sold to consumers is unregulated material, not the studied compound.
Read the evidence →Limited evidenceRung 3 of 8 · Emerging- 2Orforglipron: what the GLP-1 pill is, and what the evidence showsOrforglipron (brand name Foundayo) is a once-daily oral non-peptide GLP-1 receptor agonist that the FDA approved on April 1, 2026 for weight management in adults with obesity, or overweight with a related condition. In its phase-3 ATTAIN trials, the highest studied dose produced roughly 11–12% average weight loss over 72 weeks versus about 2% on placebo.
- 1Oral semaglutide: what the GLP-1 pill is, and what the evidence showsOral semaglutide is the same medicine as injectable semaglutide (Ozempic/Wegovy), rebuilt as a once-daily tablet using an absorption enhancer called SNAC. The low-dose tablet (Rybelsus) has been FDA-approved for type 2 diabetes since 2019; a higher-dose 25 mg tablet was approved in December 2025 for weight management — the first oral GLP-1 for weight loss. It is the same molecule and the same GLP-1 side-effect profile as the shot, so a pill is not inherently 'weaker' or 'safer,' and no head-to-head trial shows the pill beats or loses to the injection on outcomes.
- 3CagriSema: the GLP-1 + amylin combo, and what its data really showCagriSema is an investigational once-weekly injectable that combines semaglutide (a GLP-1, the drug in Wegovy and Ozempic) with cagrilintide (an amylin analog) in one fixed dose. In phase-3 trials it produced large weight loss — about 20% under real-world adherence (≈22.7% if taken exactly as intended) in obesity without diabetes — but a 2026 head-to-head trial could not prove it was non-inferior to tirzepatide, and it is not approved anywhere: Novo Nordisk filed for FDA approval in December 2025, with a decision expected during 2026. Anything sold as 'cagrilintide' or 'CagriSema' outside a clinical trial today is unregulated material, not the studied product.
- 2Can a GLP-1 treat fatty liver disease (MASH)?Yes — for the first time, a GLP-1 is an FDA-approved treatment for the serious form of fatty liver disease. In August 2025 the FDA gave accelerated approval to semaglutide 2.4 mg (Wegovy) for adults with noncirrhotic MASH (the inflammatory, scarring form) with moderate-to-advanced fibrosis. In the phase-3 ESSENCE trial about 63% of people on semaglutide had their steatohepatitis resolve without worse scarring, versus about 34% on placebo, at 72 weeks. That is a strong result on liver biopsy — but it is an 'accelerated' approval based on how the liver looks, not yet proof that the drug prevents cirrhosis, liver failure, or death. Those results are still years away.
- 7GLP-1 microdosing: what the evidence actually showsGLP-1 microdosing means using GLP-1 medicines at doses below the FDA-approved, trial-tested regimen — usually compounded and promoted online. No randomized trial has tested whether these smaller doses work or are safe. Professional societies including AACE do not support the practice, and the FDA has acted against unapproved compounded GLP-1 products.
- 1The compounded GLP-1 ban: is compounded semaglutide legal in 2026?Compounded semaglutide and tirzepatide lost their legal shortage exception in 2025 when FDA declared the shortages resolved. On April 30, 2026, FDA proposed excluding these molecules from the 503B bulks list, finding no clinical need — only cost. The proposal is not yet final, and FDA extended the public comment period to July 30, 2026, so as of this review it is still open.
Living with it
Interactions, missed doses, surgery, alcohol, birth control, and the quieting of food noise.
Can I take other medicines with my GLP-1? An interactions guide
Almost every GLP-1 interaction question traces to one thing: these medicines slow how fast the stomach empties, which can change the timing of how a swallowed drug is absorbed. For most oral medicines the total amount absorbed stays about the same, and no dose change is needed — but a few combinations genuinely deserve attention: oral birth control on tirzepatide (its label recommends a backup method for a few weeks after starting or increasing the dose), insulin and sulfonylureas (added low-blood-sugar risk), and narrow-margin drugs like warfarin (closer monitoring). This page maps which questions to ask; the one safe action is to review your full medication list with your pharmacist or prescriber.
Read the evidence →Strong evidenceRung 1 of 8 · Established- 1How long does a GLP-1 stay in your system? Half-life explainedGLP-1 medicines are weekly because they clear the body slowly. Semaglutide (Ozempic/Wegovy) has an elimination half-life of about one week, and its label says it stays in the circulation for about five weeks after the last dose. Tirzepatide (Mounjaro/Zepbound) has a half-life of about five days, so it takes on the order of three to four weeks to wash out. That long tail is why a weekly shot works steadily — and why side effects, and the drug's effects, can linger for weeks after someone stops. One labeled consequence: because semaglutide clears so slowly, its label advises stopping it at least two months before a planned pregnancy — a timing decision to make with a prescriber.
- 1Missed a GLP-1 dose? Here's what each medicine's label says to doIf you miss a weekly GLP-1 injection, each medicine's FDA label gives its own rule — and they are not all the same, so check yours. Ozempic's label says take a missed dose as soon as possible within 5 days, and skip it if more than 5 days have passed. Wegovy's label says take it only if your next scheduled dose is more than 2 days away, and skip it if that's less than 2 days off. The Mounjaro and Zepbound labels (both tirzepatide) say take it within 4 days (96 hours), and skip it after that. In each case the label then has you resume your normal weekly day and take only the one dose — never two to catch up. Ozempic and Wegovy are the same medicine (semaglutide) but have different windows, which trips people up. A single missed dose isn't an emergency: this page reports what the labels say — it is not personal medical advice, and your pharmacist can confirm your medicine's rule in under a minute.
- 2GLP-1 and surgery: do you have to stop before an operation?If you're on a GLP-1 and have surgery, an endoscopy, or any procedure with sedation coming up, the single most important thing is simple and universal: tell your surgical and anesthesia team well in advance that you take one — and don't stop it on your own without asking them. Beyond that, the advice has actually shifted. Because GLP-1s slow how fast the stomach empties, food can remain even after normal fasting (this part is well established), which in theory raises the risk of stomach contents entering the lungs under anesthesia. But large 2025 analyses have not shown (so far, in low-certainty data) that this translates into more actual aspiration events, so in October 2024 the major societies moved away from automatically stopping the medicine for everyone toward an individualized approach: most people can keep taking it, with the team assessing risk, sometimes using a longer clear-liquid diet or a bedside ultrasound, and taking full-stomach precautions during anesthesia rather than cancelling. Whether to hold your dose is a decision for your anesthesia team and you — not a rule to apply yourself.
- 3GLP-1s and alcohol: the evidence on reduced cravingsMany people on GLP-1 medicines report wanting alcohol less, and the early evidence is genuinely promising: small randomized trials and large observational studies point the same way. But this is emerging science, not settled — GLP-1s are not an approved or proven treatment for alcohol use disorder, and the effect is not guaranteed.
- 1GLP-1 medicines and birth control: what actually changesOne GLP-1-based medicine carries a specific contraception warning and the other does not, and that contrast is the single most important thing to know. Tirzepatide's FDA label (Mounjaro and Zepbound) warns that because the drug slows stomach emptying it can make oral hormonal contraceptives — birth-control pills — less reliable, and advises either switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. Semaglutide's labels (Ozempic, Wegovy, Rybelsus) do not carry this warning. The concern is specific to swallowed pills, because that is the route gastric emptying affects — non-oral methods (implant, IUD, injection, patch, vaginal ring) are not the target of the label's caution. Separately, none of these medicines is recommended in pregnancy: the labels direct stopping if pregnancy occurs, and because they clear slowly, planning a stop before trying to conceive is standard (semaglutide's label specifies at least 2 months; tirzepatide's gives no set number). 'Ozempic babies' — unexpected pregnancies — are a real, plausibly-explained phenomenon combining restored fertility after weight loss with the pill-reliability issue. Every specific decision here belongs with a prescriber, not a web page.
- 4GLP-1s, periods, and 'Ozempic babies': what's really going onTwo real things get blurred here. Menstrual changes — lighter, heavier, or skipped periods — are widely reported on GLP-1 medicines, but there's no large trial tracking cycles outside PCOS studies, so this is anecdotal and most plausibly driven by weight loss rather than a direct effect on the ovary. 'Ozempic babies' — unexpected pregnancies — are real and best explained by two things stacking: weight loss restoring ovulation in people with obesity- or PCOS-related irregular cycles, and, for tirzepatide specifically, a labeled reduction in how well oral birth-control pills are absorbed. What doesn't exist is a measured rate of pregnancies these drugs have 'caused,' and none of this makes a GLP-1 a fertility treatment.
- 3GLP-1 medicines and PCOS: what the evidence really showsFor PCOS, the honest picture is that GLP-1 medicines help with the part PCOS shares with obesity — weight and blood sugar — more than they treat PCOS itself. In women with PCOS and excess weight they produce modest short-term weight loss (supported but limited), while the reproductive benefits people hope for — more regular periods, a better chance of conceiving naturally — are real in some studies but low-certainty and inconsistent across reviews. None of these drugs is FDA-approved for PCOS or for fertility; that use is off-label. The 'Ozempic babies' phenomenon is real and mostly a weight-loss story: losing weight can restart ovulation in people who weren't ovulating, so fertility can return unexpectedly. Two safety points matter most: tirzepatide (Mounjaro/Zepbound) can make oral birth-control pills less reliable and its label says to use a backup or non-oral method — semaglutide does not carry that warning; and none of these medicines is recommended in pregnancy — clinicians treat them as a tool to use before conceiving, not during. They also aren't a first-line PCOS treatment or right for everyone, and every specific decision belongs with a clinician who knows your history.
- 2GLP-1 medicines and menopause: what actually helps, and what's hypeIn menopause, the honest picture separates three things people blur together. First, menopause does shift fat toward the belly and impose a modest metabolic headwind — but 'menopause makes you gain weight' as a simple direct cause is disputed; total gain tracks more with aging and lifestyle. Second, GLP-1 medicines work about as well in peri- and postmenopausal women as in younger women — roughly 23% vs 26% weight loss in a menopause-stratified analysis of the tirzepatide trials — so this part is real, though menopause is not an approved use (it's off-label). Third, the safety angle that matters most here is muscle and bone: some of the weight lost is muscle, and bone density dips modestly with the weight loss — but that looks weight-driven rather than a direct bone toxin, and no increase in fractures has been shown (diabetes trials even hint at fewer). The headline extras are where hype lives: the 'hormone therapy makes GLP-1s work 35% better' claim comes from one small, non-randomized study its own authors say can't prove cause, and there is no verified evidence that GLP-1s relieve hot flashes. Every specific decision belongs with a clinician who knows your history.
- 1Traveling with your GLP-1 pen: TSA, storage, and temperatureTwo rulebooks matter when you fly with a GLP-1 pen: the TSA's for getting through security, and the manufacturer's for keeping it usable. TSA explicitly allows medically necessary injectable medications in carry-on bags even above the liquid limit, along with the ice or gel packs to keep them cold — you declare them at the checkpoint. For storage, unopened pens go in the fridge (36–46°F), and each product then allows a limited stretch at room temperature: Ozempic up to 56 days, Wegovy up to 28 days, and tirzepatide (Mounjaro/Zepbound) up to 21 days. Never freeze them, keep them in the original carton to protect from light, and always pack them in your carry-on — the cargo hold can freeze them.
- 3Food noise: what it is, why GLP-1s quiet it, and why it comes backFood noise is persistent, intrusive thinking about food — a heightened form of food-cue reactivity rooted in the brain's appetite and reward circuits. GLP-1 medicines act on those same circuits, which is why many people report the noise quieting. Because the drug is doing the quieting, the noise typically returns when treatment stops.
More topics
Everything else worth knowing.
How much weight will you lose on a GLP-1? What the trials — and real life — show
In the large trials, weight-management doses of these medicines produced big average losses: semaglutide 2.4 mg (Wegovy) averaged about 15% of body weight over 68 weeks, and tirzepatide (Zepbound) averaged roughly 15–21% depending on dose over 72 weeks — versus 2–3% on placebo. But those are group averages, and individual results vary enormously: in the semaglutide trial about half of people lost 15% or more while roughly one in seven didn't reach even 5%. Real-world results are typically lower than the trials — around 9% at one year in a large clinical cohort — mostly because many people stop early or never reach the full dose. And weight tends to return after stopping. So the honest answer isn't a number you can count on; it's a range, driven by dose, how long you stay on, and your own biology. This page reports what the studies found and is not a prediction of your result or medical advice.
Read the evidence →Strong evidenceRung 1 of 8 · Established- 1GLP-1 dose escalation: why you start low and step up, and what each label saysGLP-1 medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are started at a low dose and increased in steps over several months because their FDA labels build in that escalation for one stated reason: to reduce gastrointestinal side effects like nausea. Each label defines a starting dose that is a tolerance-building "runway," not a treatment target, then a series of higher steps held for a minimum interval (generally at least four weeks) before any increase — and the labels describe increases as individualized and prescriber-directed. This page explains why that gradual approach works and reports what the approved labels say; it is not medical advice or a dosing schedule to follow on your own. Your actual dose and timing are a decision for the clinician who prescribes it.
- 1Mounjaro vs. Zepbound: same molecule, two different labelsMounjaro and Zepbound are the same active molecule — tirzepatide, made by Eli Lilly — sold under two brand names with different FDA-approved uses. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Because the approved use differs, insurance often treats them very differently, even though the drug inside is the same.
No answers match — try a different word or filter.